葡萄糖转运体-2 抑制剂 (SGLT2Is) -TLRs轴调节糖尿病
Amirhossein Niknejad1,2, Yasamin Hosseini1,2, Hedieh Sadat Shamsnia1,2
1Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Cell biochemistry and biophysics
|September 1, 2023
概括
糖转运体-2 抑制剂 (SGLT2Is) 除了降低葡萄糖,还提供独特的益处,包括心血管和脏的保护. 本综述探讨了SGLT2Is如何影响收费类受体 (TLR) 途径,可能减轻糖尿病并发症.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病影响全球数以百万计的人,其特点是胰岛素功能受损.
- 糖转运体-2 抑制剂 (SGLT2Is) 是一种具有独特机制的近期口服抗糖尿病药物.
- 即使在非糖尿病患者中,SGLT2Is也表现出超出血糖控制的好处,包括心血管和脏保护.
研究的目的:
- 为了研究SGLT2抑制剂对收费类受体 (TLR) 途径的影响.
- 确定SGLT2抑制对TLRs的影响是否有利于管理糖尿病及其并发症.
- 在糖尿病的背景下探索SGLT2Is的抗炎和氧化减压特性.
主要方法:
- 对调查SGLT2抑制剂及其与免疫系统相互作用的研究的文献综述.
- 对类似收费受体 (TLR) 的研究分析及其在糖尿病相关的炎症过程中的作用.
- 对SGLT2Is的抗炎和抗氧化作用的综合数据.
主要成果:
- SGLT2 抑制剂调节免疫细胞激活,降低氧化应激,缓解炎症,从而缓解糖尿病并发症.
- 收费类受体 (TLRs) 是免疫和炎症反应的关键调解者,与糖尿病并发症有关.
- SGLT2Is具有抗炎和抗氧化特性,可能有利于影响TLR途径.
结论:
- SGLT2 抑制剂具有超出降血糖范围的多益性作用.
- SGLT2 抑制剂与TLR 途径之间的相互作用为治疗糖尿病并发症提供了一个有前途的治疗途径.
- 需要进一步的研究,以充分阐明SGLT2Is对糖尿病中TLR介导炎症的有益作用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Glucose Absorption Into the Small Intestine
31.8K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K


